Critical Comparison: Indivior (INDV) & Its Rivals

Indivior (NASDAQ:INDV) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Indivior to similar companies based on the strength of its dividends, institutional ownership, analyst recommendations, profitability, earnings, valuation and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Indivior and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0	1	4	1	3.00
Indivior Competitors	7819	13779	25785	1035	2.41

Indivior currently has a consensus price target of $46.40, indicating a potential upside of 64.48%. As a group, “Pharmaceuticals” companies have a potential upside of 24.25%. Given Indivior’s stronger consensus rating and higher probable upside, analysts plainly believe Indivior is more favorable than its competitors.

Earnings and Valuation

This table compares Indivior and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Indivior	$1.37 billion	$210.00 million	7.88
Indivior Competitors	$5.38 billion	$3.23 billion	555.01

Indivior’s competitors have higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Indivior has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Indivior’s competitors have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.

Profitability

This table compares Indivior and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Indivior	32.75%	-418.04%	42.96%
Indivior Competitors	-2,393.16%	-220.83%	-16.11%

Insider and Institutional Ownership

60.3% of Indivior shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Indivior beats its competitors on 8 of the 13 factors compared.

About Indivior

Indivior is a specialty pharmaceutical company focused on developing and providing treatments for substance use disorders and serious mental illness. Its products include medicines for opioid use disorder, such as Sublocade, a long-acting injectable form of buprenorphine, and Suboxone, a buprenorphine-and-naloxone treatment. The company also markets Opvee, a nasal spray used to reverse opioid overdose, and Perseris, a long-acting injectable treatment for schizophrenia. Indivior develops additional therapies through its research and development programs.